AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29424934 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual structured and qualified feedback (FB) after pre-assessment
Number of subjects: 53
Study 29424934 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 53
Study 27479106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Group Therapy (CBGT) with e-mail support
Number of subjects: 91
Study 27479106 — intervention group
Group type: COMPARATOR
Intervention: Cognitive Behavioral Group Therapy (CBGT) without e-mail support
Number of subjects: 91
Study 24549763 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT) with 1,000 impulses
Number of subjects: 26
Study 24549763 — intervention group
Group type: COMPARATOR
Intervention: Placebo group treated with deactivated shock wave applicator
Number of subjects: 26
Study 24549763 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy (ESWT)
Number of subjects: 26
Study 24549763 — intervention group
Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 26
Study 22294812 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 nights of total sleep deprivation (TSD) and one night of recovery sleep
Number of subjects: 24
Study 22294812 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 24
Study 20043965 — intervention group
Group type: EXPERIMENTAL
Intervention: Tempting, high caloric food choice
Number of subjects: 0
Study 20043965 — intervention group
Group type: COMPARATOR
Intervention: No tempting food choice (control)
Number of subjects: 0
Study 18464752 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-weight loss obese subjects
Number of subjects: 6
Study 18464752 — intervention group
Group type: COMPARATOR
Intervention: Nonobese subjects (Control)
Number of subjects: 6
Study 18464752 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-weight loss obese subjects
Number of subjects: 6
Study 15894962 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevelamer
Number of subjects: 108
Study 15894962 — intervention group
Group type: COMPARATOR
Intervention: Calcium acetate
Number of subjects: 108
Study 13677125 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 g Owen Mumford monofilament sensory testing
Number of subjects: 0
Study 9892256 — intervention group
Group type: EXPERIMENTAL
Intervention: Bereavement support group intervention
Number of subjects: 166
Study 9892256 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 166
Study 9346691 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous insulin bolus (666 mU . kg‐1) followed by infusion at 500 mU.m‐2.min‐1 until 3 hours after portal vein unclamping.
Number of subjects: 20
Study 9346691 — intervention group
Group type: COMPARATOR
Intervention: No exogenous insulin administered.
Number of subjects: 20
Study 1816197 — intervention group
Group type: EXPERIMENTAL
Intervention: Enoxacin
Number of subjects: 0
Study 1816197 — intervention group
Group type: COMPARATOR
Intervention: Ceftazidime
Number of subjects: 0
Study 7080885 — intervention group
Group type: EXPERIMENTAL
Intervention: Home correspondence program conducted entirely by mail
Number of subjects: 87
Study 7080885 — intervention group
Group type: EXPERIMENTAL
Intervention: Mail program with supplemental financial contingency contracts tied to completion of written homework
Number of subjects: 87
Study 7080885 — intervention group
Group type: EXPERIMENTAL
Intervention: Correspondence programs supplemented by homework contracts and regular calls to a telephone answering system
Number of subjects: 87
Study 7080885 — intervention group
Group type: COMPARATOR
Intervention: Standard behavioral group program
Number of subjects: 87
Study 28627737 — intervention group
Group type: EXPERIMENTAL
Intervention: ICDAS (IC)
Number of subjects: 8
Study 28627737 — intervention group
Group type: EXPERIMENTAL
Intervention: Nyvad's (NY)
Number of subjects: 8
Study 28627737 — intervention group
Group type: COMPARATOR
Intervention: Conventional Visual Clinical Examination (CVCE)
Number of subjects: 8
Study 27296819 — intervention group
Group type: EXPERIMENTAL
Intervention: Aclidinium 400 μg/formoterol 12 μg
Number of subjects: 590
Study 27296819 — intervention group
Group type: COMPARATOR
Intervention: Formoterol 12 μg
Number of subjects: 590
Study 24532007 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg tideglusib
Number of subjects: 146
Study 24532007 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 mg tideglusib
Number of subjects: 146
Study 24532007 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 146
Study 22801818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diagnostic puncture of the renal pelvis
Number of subjects: 148
Study 20381156 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants
Number of subjects: 372
Study 20381156 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotherapies
Number of subjects: 372
Study 18671615 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial suture (AMS)
Number of subjects: 61
Study 18671615 — intervention group
Group type: COMPARATOR
Intervention: Conventional suture (control)
Number of subjects: 61
Study 15908835 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS XR 10 mg once daily, with 10 mg weekly dose increases to a maximum of 30 mg/d
Number of subjects: 568
Study 15651745 — intervention group
Group type: EXPERIMENTAL
Intervention: HAART
Number of subjects: 0
Study 15651745 — intervention group
Group type: COMPARATOR
Intervention: Observational studies
Number of subjects: 0
Study 10917210 — intervention group
Group type: EXPERIMENTAL
Intervention: Intratumoral injection of a replication-defective adenoviral expression vector containing wild-type p53
Number of subjects: 6
Study 9347431 — intervention group
Group type: EXPERIMENTAL
Intervention: ondansetron 100 mcg/kg
Number of subjects: 160
Study 9347431 — intervention group
Group type: EXPERIMENTAL
Intervention: droperidol 75 mcg/kg
Number of subjects: 160
Study 9347431 — intervention group
Group type: COMPARATOR
Intervention: metoclopramide 250 mcg/kg
Number of subjects: 160
Study 9347431 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 160
Study 8191134 — intervention group
Group type: EXPERIMENTAL
Intervention: Miocamycin (15 mg/kg/day bid per os)
Number of subjects: 149
Study 8191134 — intervention group
Group type: COMPARATOR
Intervention: Benzathine penicillin G (600,000 or 1,200,000 units, single injection)
Number of subjects: 149
Study 3083712 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (SNP)
Number of subjects: 27
Study 3083712 — intervention group
Group type: COMPARATOR
Intervention: Nitroglycerin (NTG)
Number of subjects: 27
Study 3083712 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (25 mg orally) with SNP
Number of subjects: 27
Study 31698336 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 steps per day (basic intervention)
Number of subjects: 120
Study 31698336 — intervention group
Group type: EXPERIMENTAL
Intervention: 10,000 steps per day and at least 30 minutes in moderate intensity (enhanced intervention)
Number of subjects: 120
Study 31698336 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 120
Study 30522462 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet use during total knee replacement
Number of subjects: 0
Study 26796192 — intervention group
Group type: EXPERIMENTAL
Intervention: Midseptal lead positioning
Number of subjects: 226
Study 26796192 — intervention group
Group type: COMPARATOR
Intervention: Apical lead positioning
Number of subjects: 226
Study 24445685 — intervention group
Group type: EXPERIMENTAL
Intervention: 600 mg oral n-acetyl cysteine twice daily
Number of subjects: 30
Study 24445685 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 22730694 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug treatment group
Number of subjects: 34
Study 22730694 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex treatment group
Number of subjects: 34
Study 22730694 — intervention group
Group type: EXPERIMENTAL
Intervention: Tetrandrine combined with whole-lung lavage
Number of subjects: 34
Study 22730694 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 34
Study 20556437 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB) with 5 mL of 0.5% levobupivacaine
Number of subjects: 60
Study 20556437 — intervention group
Group type: COMPARATOR
Intervention: Fast-track general anesthesia (GA) via laryngeal mask airway (LMA)
Number of subjects: 60
Study 20556437 — intervention group
Group type: EXPERIMENTAL
Intervention: Paravertebral block (PVB)
Number of subjects: 60
Study 18448318 — intervention group
Group type: EXPERIMENTAL
Intervention: k-NN algorithm with feature selection
Number of subjects: 26
Study 18448318 — intervention group
Group type: EXPERIMENTAL
Intervention: k-NN algorithm with non-binary weights
Number of subjects: 26
Study 18448318 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-variable classifier based on choline-to-NAA abnormality index
Number of subjects: 26
Study 18448318 — intervention group
Group type: EXPERIMENTAL
Intervention: k-NN results
Number of subjects: 26
Study 16167284 — intervention group
Group type: EXPERIMENTAL
Intervention: Tobramycin enhanced viscosity ophthalmic solution (3 mg/mL) given twice daily (BID) for 7 days
Number of subjects: 276
Study 16167284 — intervention group
Group type: COMPARATOR
Intervention: Tobramycin 0.3% ophthalmic solution (3 mg/mL) given four times daily (QID) for 7 days
Number of subjects: 276
Study 15307418 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic Chagas disease patients
Number of subjects: 133
Study 10087016 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg of caffeine consumed as a single dose in the morning
Number of subjects: 0
Study 10087016 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine maintenance doses of 100, 300, and 600 mg/day
Number of subjects: 0
Study 10087016 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg caffeine/day with lower doses (200, 100, 50, 25, and 0 mg/day)
Number of subjects: 0
Study 10087016 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg/day for 1, 3, 7, or 14 days
Number of subjects: 0
Study 7612769 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide 10 mg intravenously (4 doses starting at induction of anaesthesia)
Number of subjects: 100
Study 7612769 — intervention group
Group type: COMPARATOR
Intervention: Hyoscine transdermally (patch placed behind the ear at 0600 h on the day of operation)
Number of subjects: 100
Study 2403905 — intervention group
Group type: EXPERIMENTAL
Intervention: Infrared photocoagulation (IRPC)
Number of subjects: 102
Study 2403905 — intervention group
Group type: COMPARATOR
Intervention: Bipolar diathermy (BD)
Number of subjects: 102
Study 363105 — intervention group
Group type: EXPERIMENTAL
Intervention: Timolol maleate
Number of subjects: 23
Study 363105 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 31608549 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofogliflozin (TOFO)
Number of subjects: 774
Study 29315187 — intervention group
Group type: EXPERIMENTAL
Intervention: System A
Number of subjects: 120
Study 29315187 — intervention group
Group type: EXPERIMENTAL
Intervention: System B
Number of subjects: 120
Study 28033244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 (100,000 units single oral dose)
Number of subjects: 120
Study 28033244 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study 28033244 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3
Number of subjects: 120
Study 23903022 — intervention group
Group type: COMPARATOR
Intervention: 10 mg/kg bolus followed by 1 mg·kg·h infusion (low dose)
Number of subjects: 569
Study 23903022 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/kg bolus followed by 16 mg·kg·h infusion (high dose)
Number of subjects: 569
Study 21923569 — intervention group
Group type: EXPERIMENTAL
Intervention: Support group intervention at the Foundation Lustgården Mälardalen, lasting one week on a residential basis followed by four days of follow-up two months later.
Number of subjects: 382
Study 21923569 — intervention group
Group type: COMPARATOR
Intervention: Standard follow‐up routines (Control group)
Number of subjects: 382
Study 19937152 — intervention group
Group type: EXPERIMENTAL
Intervention: Postbariatric abdominoplasty
Number of subjects: 80
Study 19937152 — intervention group
Group type: COMPARATOR
Intervention: Control procedures (never obese women)
Number of subjects: 80
Study 18689382 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg 1 time/d
Number of subjects: 1108
Study 18689382 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 microg 4 times/d
Number of subjects: 1108
Study 18689382 — intervention group
Group type: EXPERIMENTAL
Intervention: 400 microg 1 time/d
Number of subjects: 1108
Study 18689382 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg 4 times/d
Number of subjects: 1108
Study 18689382 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 microg 1 time/d
Number of subjects: 1108
Study 18689382 — intervention group
Group type: EXPERIMENTAL
Intervention: 4000 microg 1 time/wk
Number of subjects: 1108
Study 18689382 — intervention group
Group type: COMPARATOR
Intervention: Cessation of folic acid
Number of subjects: 1108
Study 15899163 — intervention group
Group type: EXPERIMENTAL
Intervention: 105 mg of elemental iron daily p.o.
Number of subjects: 0
Study 15899163 — intervention group
Group type: EXPERIMENTAL
Intervention: 105 mg of elemental iron daily and 5 mg of folic acid daily p.o.
Number of subjects: 0
Study 15899163 — intervention group
Group type: COMPARATOR
Intervention: No vitamin supplements (control group)
Number of subjects: 0
Study 14565892 — intervention group
Group type: EXPERIMENTAL
Intervention: Pure self-help (without guidance)
Number of subjects: 31
Study 14565892 — intervention group
Group type: EXPERIMENTAL
Intervention: Guided self-help (with guidance)
Number of subjects: 31
Study 14565892 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment completers (N = 18)
Number of subjects: 31
Study 14565892 — intervention group
Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 31
Study 14565892 — intervention group
Group type: COMPARATOR
Intervention: Follow-up (6 months post-treatment)
Number of subjects: 31
Study 10037634 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin A (7000 micrograms retinol equivalents)
Number of subjects: 44646
Study 10037634 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta carotene (42 mg, or 7000 micrograms retinol equivalents)
Number of subjects: 44646
Study 10037634 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined vitamin A or beta carotene
Number of subjects: 44646
Study 10037634 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44646
Study 8650042 — intervention group
Group type: EXPERIMENTAL
Intervention: d-penicillamine treatment
Number of subjects: 9
Study 8650042 — intervention group
Group type: COMPARATOR
Intervention: Other liver diseases (control group)
Number of subjects: 9
Study 2180090 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg miglitol
Number of subjects: 11
Study 7011163 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcutaneous nerve stimulation (TNS)
Number of subjects: 100
Study 7011163 — intervention group
Group type: COMPARATOR
Intervention: Control group (no TNS)
Number of subjects: 100
Study 6338889 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 204
Study 6338889 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 30854700 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori population screening and eradication
Number of subjects: 8658
Study 30144629 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard In-Office Cognitive Processing Therapy (CPT)
Number of subjects: 0
Study 30144629 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home Telebehavioral Health CPT
Number of subjects: 0
Study 30144629 — intervention group
Group type: EXPERIMENTAL
Intervention: In-Home CPT (provider delivers treatment in participant's home)
Number of subjects: 0
Study 26754749 — intervention group
Group type: EXPERIMENTAL
Intervention: HPC + trehalose
Number of subjects: 2532
Study 26754749 — intervention group
Group type: COMPARATOR
Intervention: SSS + sucrose
Number of subjects: 2532
Study 24126617 — intervention group
Group type: EXPERIMENTAL
Intervention: Train-of-four (TOF) monitoring
Number of subjects: 44
Study 22244363 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiple micronutrient-fortified biscuits (FB)
Number of subjects: 403
Study 22244363 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly iron supplementation (SUP)
Number of subjects: 403
Study 22244363 — intervention group
Group type: COMPARATOR
Intervention: Control group (C)
Number of subjects: 403
Study 20102884 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasminogen activator inhibitor-1 (PAI-1) antigen
Number of subjects: 2321
Study 20102884 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1 activity
Number of subjects: 2321
Study 20102884 — intervention group
Group type: EXPERIMENTAL
Intervention: PAI-1 to tissue-type plasminogen activator ratio
Number of subjects: 2321
Study 20102884 — intervention group
Group type: EXPERIMENTAL
Intervention: D-dimer
Number of subjects: 2321
Study 20102884 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrinogen level
Number of subjects: 2321
Study 20102884 — intervention group
Group type: EXPERIMENTAL
Intervention: Tissue-type plasminogen activator antigen
Number of subjects: 2321
Study 17375984 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human porphobilinogen deaminase (P 9808) at doses of 0.5, 1, 2, and 4 mg/kg bodyweight
Number of subjects: 40
Study 17375984 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant human porphobilinogen deaminase (P 9808)
Number of subjects: 40
Study 16327349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sprotte 24 g atraumatic spinal needle
Number of subjects: 342
Study 12034928 — intervention group
Group type: COMPARATOR
Intervention: Ultrasonography (US) only
Number of subjects: 600
Study 12034928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) with abdominal computed tomography (CT)
Number of subjects: 600
Study 12034928 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography (US) in all patients
Number of subjects: 600
Study 12034928 — intervention group
Group type: EXPERIMENTAL
Intervention: Computed tomography (CT) in 317 patients
Number of subjects: 600
Study 12034928 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall negative appendectomy rate
Number of subjects: 600
Study 12034928 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall perforation rate
Number of subjects: 600
Study 9457145 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 or 12 mg)
Number of subjects: 116
Study 9457145 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine (4 mg)
Number of subjects: 116
Study 9457145 — intervention group
Group type: COMPARATOR
Intervention: Methadone (20 or 65 mg)
Number of subjects: 116
Study 9457145 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine
Number of subjects: 116
Study 7631401 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP)
Number of subjects: 70
Study 7631401 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative hemodilution (IH)
Number of subjects: 70
Study 7631401 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 70
Study 2649300 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg nicardipine t.i.d.
Number of subjects: 151
Study 2649300 — intervention group
Group type: COMPARATOR
Intervention: 25 mg hydrochlorothiazide b.i.d.
Number of subjects: 151
Study 37848 — intervention group
Group type: EXPERIMENTAL
Intervention: MIF (melanocyte-stimulating hormone-release inhibiting factor) 200 mg i.v.
Number of subjects: 12
Study 37848 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 12
Study 30797746 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment (QVM+)
Number of subjects: 125
Study 30797746 — intervention group
Group type: EXPERIMENTAL
Intervention: Endobronchial coil treatment (QVM-)
Number of subjects: 125
Study 30797746 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 125
Study 27928851 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg intravenous parecoxib
Number of subjects: 82
Study 27928851 — intervention group
Group type: COMPARATOR
Intervention: Normal saline solution (control)
Number of subjects: 82
Study 26481218 — intervention group
Group type: EXPERIMENTAL
Intervention: Trauma card group
Number of subjects: 86
Study 26481218 — intervention group
Group type: COMPARATOR
Intervention: Direct instruction group
Number of subjects: 86
Study 23706505 — intervention group
Group type: EXPERIMENTAL
Intervention: Training Group (TG) - Unilateral balance training for the right leg for six weeks
Number of subjects: 23
Study 23706505 — intervention group
Group type: COMPARATOR
Intervention: Control Group (CG) - No training
Number of subjects: 23
Study 21940143 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevel-up phaco tip position
Number of subjects: 60
Study 21940143 — intervention group
Group type: COMPARATOR
Intervention: Bevel-down phaco tip position
Number of subjects: 60
Study 19390518 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle intervention
Number of subjects: 3064
Study 19390518 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 3064
Study 19390518 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 3064
Study 19390518 — intervention group
Group type: EXPERIMENTAL
Intervention: Weight loss (5 kg)
Number of subjects: 3064
Study 19390518 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher baseline obesity severity
Number of subjects: 3064
Study 19390518 — intervention group
Group type: EXPERIMENTAL
Intervention: SF-6D improvements
Number of subjects: 3064
Study 17544774 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium hyaluronate 1%
Number of subjects: 40
Study 17544774 — intervention group
Group type: COMPARATOR
Intervention: Hydroxypropylmethylcellulose 2%
Number of subjects: 40
Study 15592334 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (10.0 microg/kg, intravenous)
Number of subjects: 48
Study 15592334 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (2.0 microg/kg, subcutaneous)
Number of subjects: 48
Study 15592334 — intervention group
Group type: EXPERIMENTAL
Intervention: AMG 531 (1.0 microg/kg, intravenous and subcutaneous)
Number of subjects: 48